Rezolute Inc (RZLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rezolute Inc (RZLT) has a cash flow conversion efficiency ratio of -0.118x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-17.43 Million) by net assets ($147.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rezolute Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rezolute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Rezolute Inc (RZLT) total liabilities for a breakdown of total debt and financial obligations.
Rezolute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rezolute Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tudor Gold Corp
V:TUD
|
-0.003x |
|
Jiangsu Jingyuan Environmental Protection Co Ltd
SHG:688096
|
0.010x |
|
STEP Energy Services Ltd
TO:STEP
|
0.058x |
|
China Reform Culture Holdings Co Ltd
SHG:600636
|
0.004x |
|
Asiacement
KO:183190
|
0.012x |
|
Siddhi Acquisition Corp Class A Common stock
NASDAQ:SDHI
|
0.000x |
|
Izertis Sa
MC:IZER
|
0.261x |
|
Polaris Media
OL:POL
|
0.072x |
Annual Cash Flow Conversion Efficiency for Rezolute Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rezolute Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see RZLT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $162.13 Million | $-69.08 Million | -0.426x | +10.13% |
| 2024-06-30 | $121.00 Million | $-57.37 Million | -0.474x | -23.82% |
| 2023-06-30 | $116.17 Million | $-44.48 Million | -0.383x | -44.46% |
| 2022-06-30 | $149.47 Million | $-39.62 Million | -0.265x | +66.16% |
| 2021-06-30 | $26.10 Million | $-20.44 Million | -0.783x | +76.13% |
| 2020-06-30 | $7.37 Million | $-24.17 Million | -3.281x | +62.43% |
| 2019-06-30 | $1.75 Million | $-15.30 Million | -8.735x | -345.15% |
| 2018-06-30 | $-3.96 Million | $-14.11 Million | 3.563x | +328.28% |
| 2017-06-30 | $8.53 Million | $-13.31 Million | -1.561x | -30.56% |
| 2016-06-30 | $8.77 Million | $-10.49 Million | -1.196x | -52.91% |
| 2015-06-30 | $9.05 Million | $-7.08 Million | -0.782x | -58.15% |
| 2014-06-30 | $6.41 Million | $-3.17 Million | -0.494x | -226.40% |
| 2013-06-30 | $-4.16 Million | $-1.63 Million | 0.391x | -94.76% |
| 2012-06-30 | $-5.41K | $-40.40K | 7.462x | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more